FluxMPS™ Dulbecco's Modified Eagle Medium (DMEM), High Glucose & 25mM HEPES w/o L-Glutamine, Sodium Pyruvate, Phenol Red: 1X Liquid

FluxMPS™ Dulbecco's Modified Eagle Medium (DMEM), High Glucose & 25mM HEPES w/o L-Glutamine, Sodium Pyruvate, Phenol Red: 1X Liquid

FluxMPS™ DCP-DMEMH-QPR1X is an MPS-grade, ultra-filtered DMEM High Glucose (4.5 g/L) formulation with 25 mM HEPES buffer, engineered for organ-on-a-chip (OoC), microphysiological systems, and CO₂-independent or open-top microfluidic platforms. Processed through a Quadruple-stage filtration system (0.1 µm ×2 + 0.04 µm ×2), it delivers approximately 5× lower particulate counts than conventional 0.22 µm–filtered media. HEPES (25 mM, pKa 7.3 at 37°C) provides robust CO₂-independent pH buffering. Formulation: [+] High Glucose (4500 mg/L), [+] Sodium Bicarbonate, [+] 25mM HEPES | [-] L-Glutamine, [-] Sodium Pyruvate, [-] Phenol Red.

• High Glucose (4.5 g/L) — supports neurons, cardiomyocytes, cancer lines, and aerobically active cells
• 25 mM HEPES (pKa 7.3 at 37°C) — robust pH buffering independent of CO₂ tension
• 0.04 µm final nano-filtration — sub-mycoplasma purity for microfluidic channels below 100 µm
• Quadruple-stage filtration: 0.1 µm pre-I → 0.04 µm pre-II → 0.1 µm sterile-I → 0.04 µm final polish
• Endotoxin < 0.05 EU/mL (LAL, USP <85>)
• Ultrapure Type 1 water (18.2 MΩ·cm), ISO 13485:2016 QMS, ISO Class 5 fill
• Custom pH, salts, glucose, HEPES concentration, and nutrient adjustments available on request

Engineered where standard media fails

Conventional 0.22 µm–filtered DMEM passes mycoplasma, subvisible particulates, and endotoxin fragments that clog microfluidic channels. Standard DMEM also lacks HEPES buffering, causing pH instability whenever chips are handled outside incubators. FluxMPS™ addresses both failure modes simultaneously.

Quadruple-stage filtration system

Four serial filtration stages reaching a final 0.04 µm polish under ISO Class 5 aseptic conditions — delivering sub-mycoplasma purity unavailable from conventional 0.22 µm media.

1. 1

   0.1 µm Pre-filtration I — Large Particulate Removal

   Removes large aggregates and contaminants; protects downstream 0.04 µm membranes and chip geometries.

2. 2

   0.04 µm Pre-filtration II — Mycoplasma Barrier

   Retains mycoplasma (0.1–0.3 µm) and fine particulates — absent from standard 0.22 µm filtration.

3. 3

   0.1 µm Sterile-filtration I — Second-pass Redundancy

   Second-pass sterility redundancy; no breakthrough from Stage 1.

4. 4

   0.04 µm Sterile-filtration II — Final Polish

   Ultimate sub-mycoplasma polish; ISO Class 5 aseptic fill & finish.

Designed for next-generation cell models

FluxMPS™ DCP-DMEMH-QPR1X combines high-glucose energy support with HEPES pH stability — supporting demanding platforms from open-top microfluidic chips and CO₂-free bioreactors to multi-organ body-on-a-chip systems.

Automated Bioreactors & Robotics

HEPES buffering eliminates CO₂ dependency in automated bioreactor perfusion. An optional 0.01 µm (10 nm) ultra-filtered variant is available on request for robotic liquid handlers where even trace particulates cause valve failure.

• Total Particulate Exclusion: 10 nm filtration removes nanoparticulate aggregates from bioreactor media lines
• pH-Stable Automated Delivery: HEPES maintains pH during robotic media exchanges without CO₂ re-equilibration delays
• Extended Perfusion Stability: Consistent high-glucose delivery with stable pH over weeks-long culture

Inquiry Required: Contact support@diagnocine.com for the 0.01 µm variant.

Analytical release specifications

Every lot released against the full specification matrix. CoA: support@diagnocine.com.

Full composition (mg/L)

DMEM High Glucose + HEPES is a modification of Basal Medium Eagle (BME) with 4× BME amino acid and vitamin concentrations. 31 ingredients verified per lot with CAS numbers for full raw-material traceability. HEPES (25 mM = 5958 mg/L) is listed in the OTHERS tab.

Manufacturing & compliance

Every FluxMPS™ product is manufactured and released under a rigorous multi-layer quality system spanning raw materials, in-process controls, and final-product testing.

How DCP-DMEMH-QPR1X compares

FluxMPS™ DCP-DMEMH-QPR1X vs. conventional 0.22 µm–filtered DMEM High Glucose formulations.

Frequently asked questions

Common questions about FluxMPS™ DCP-DMEMH-QPR1X DMEM High Glucose + 25mM HEPES.

Supporting literature

Key peer-reviewed publications supporting MPS-grade, HEPES-buffered, ultra-filtered DMEM High Glucose in organ-on-a-chip and metabolic research.

1. Huh D, et al. Reconstituting organ-level lung functions on a chip. Science. 2010;328:1662–1668. doi:10.1126/science.1188302
2. Bhatia SN, Ingber DE. Microfluidic organs-on-chips. Nat Biotechnol. 2014;32:760–772. doi:10.1038/nbt.2989
3. Warburg O. On the origin of cancer cells. Science. 1956;123:309–314. doi:10.1126/science.123.3191.309
4. Novak R, et al. Robotic fluidic coupling and interrogation of multiple vascularized organ chips. Nat Biomed Eng. 2020;4:407–420. doi:10.1038/s41551-019-0497-x
5. Katt ME, et al. In vitro tumor models: advantages, disadvantages, variables, and selecting the right platform. Front Bioeng Biotechnol. 2016;4:12. doi:10.3389/fbioe.2016.00012
6. Jang KJ, et al. Human kidney proximal tubule-on-a-chip for drug transport and nephrotoxicity assessment. Integr Biol. 2013;5:1119–1129. doi:10.1039/c3ib40049b
7. Schimek K, et al. Integrating biological vasculature into a multi-organ-chip microsystem. Lab Chip. 2013;13:3588–3598. doi:10.1039/c3lc50217a
8. Luni C, et al. High-efficiency cellular reprogramming with microfluidics. Nat Methods. 2016;13:446–452. doi:10.1038/nmeth.3832
9. Sung JH, et al. Microfabricated mammalian organ systems and their integration into models of whole animals and humans. Lab Chip. 2013;13:1201–1212. doi:10.1039/c3lc41017j